Securities fraud investigation at courthouse

Open Settlements for Investors

Court-approved settlements are in progress. Check if you qualify to claim money.

Total Settlement Funds Currently Available

$387,975,000

Evolv Technologies Holdings, Inc. (EVLV)

Settlement Fund: $15,000,000

Claim Deadline: August 12, 2026(1 Day Left)

Hearing Date: September 24, 2026

Class Period: June 28, 2021 - January 22, 2025

SolarEdge Technologies, Inc. (SEDG)

Settlement Fund: $55,000,000

Claim Deadline: August 17, 2026(6 Days Left)

Hearing Date: August 24, 2026

Class Period: February 13, 2023 - January 17, 2024

VNET Group, Inc. (VNET)

Settlement Fund: $5,875,000

Claim Deadline: August 20, 2026(9 Days Left)

Hearing Date: August 27, 2026

Class Period: March 22, 2022 - May 18, 2023

Shoals Technologies Group, Inc. (SHLS)

Settlement Fund: $70,000,000

Claim Deadline: August 25, 2026(14 Days Left)

Hearing Date: September 28, 2026

Class Period: May 15, 2022 - February 10, 2025

Revance Therapeutics, Inc. (RVNC)

Settlement Fund: $17,000,000

Claim Deadline: August 28, 2026(17 Days Left)

Hearing Date: August 10, 2026

Class Period: February 29, 2024 - February 28, 2025

Amylyx Pharmaceuticals, Inc. (AMLX)

Settlement Fund: $6,500,000

Claim Deadline: August 31, 2026(20 Days Left)

Hearing Date: September 10, 2026

Class Period: November 10, 2022 - February 6, 2024

Danaher Corporation (DHR)

Settlement Fund: $172,500,000

Claim Deadline: September 20, 2026(40 Days Left)

Hearing Date: September 3, 2026

Class Period: January 26, 2022 - January 19, 2024

TAL Education Group (TAL)

Settlement Fund: $14,100,000

Claim Deadline: September 29, 2026(49 Days Left)

Hearing Date: October 29, 2026

Class Period: January 13, 2022 - June 12, 2023

Stitch Fix, Inc. (SFIX)

Settlement Fund: $32,000,000

Claim Deadline: October 7, 2026(57 Days Left)

Hearing Date: September 24, 2026

Class Period: June 8, 2020 - September 7, 2022

Didn't Find Your Settlement?

See ongoing shareholder cases and discover which companies are still under review.